Paradigm Biopharmaceuticals Ltd has released a press release.
Published Canine Study Strengthens iPPS Phase 3 Rationale
Filed with ASX ·
6ix hasn’t read this filing yet.
Paradigm Biopharmaceuticals Ltd. on 6ix
Story so far
Earlier from Paradigm Biopharmaceuticals
- Oral OA Animal Therapy Progresses via AVet Deal
- December 2025 Quarterly Activities Report & Appendix 4C
- iPPS Phase 2 Biomarker Results Published in Leading Journal
- Phase 3 Knee OA Trial Recruitment Update
- Drawdown of Tranche 2 under the Convertible Note Facility
Later from Paradigm Biopharmaceuticals
- Drawdown of Tranche 3 under the Convertible Note Facility
- Appendix 4D and Half Year Report
- Paradigm Achieves 50% Patient Dosing in Phase 3
- Upsized $14M Placement Extends Runway Post IA
- March 2026 Quarterly Activities Report & Appendix 4C
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals